Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

TPX-0131-01 : A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC

Male or<br/>FemaleGender Male or

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung

Systemic therapy | LungNon-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This Phase I/II trial is trying to understand how safe and effective a targeted therapy (TPX-0131) is in people with ALK+ advanced or metastatic Non-Small Cell Lung Cancer.

This trial is treating patients with Non-Small Cell Lung Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1/2 Study of TPX-0131, A Novel Oral ALK Tyrosine Kinase Inhibitor in Subjects With ALK+ Advanced or Metastatic NSCLC

Commercial Sponsor

Turning Point Therapeutics, Inc.


This trial has two experimental phases. Phase 1 is assessing the safety, tolerability, PK, MTD, and RP2D of TPX-0131. Phase 2 will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts. Participants will receive TPX-0131 via oral tablets.

Not Recruiting Hospitals Read MoreRead more


Austin Health
Ms Samantha Chakar
03 9496 3088

PCCTU (Parkville Cancer Clinical Trials Unit) *
Rachel McMenamin

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.